All In Biotech

Drug Trial Radar · NCT06746402

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

A Phase 1, Two-Part, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986278 (Part A) and a Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization (Part B) in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Feb 10, 2025

Primary completion

Sep 11, 2025

Study completion Sep 11, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • BMS-986278Drug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

  • MoxifloxacinDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with non-serious Adverse Events (AEs)Time frame: Until 28 days post last treatment dose
  2. Number of participants with Serious AEs (SAEs)Time frame: Until 28 days post last treatment dose
  3. Number of participants with AEs leading to study intervention discontinuationTime frame: Until 28 days post last treatment dose
  4. Number of participants with vital sign abnormalitiesTime frame: Up to Day 18
  5. Number of participants with clinical laboratory assessment abnormalitiesTime frame: Up to Day 18
  6. Number of participants with 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Up to Day 18
  7. Number of participants with physical examination abnormalitiesTime frame: Up to Day 18
  8. Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)Time frame: Up to Day 13 of Period 4 (Each period is 17 days)
  9. Placebo-corrected change from baseline QTcF (ΔΔQTcF)Time frame: Up to Day 13 of Period 4 (Each period is 17 days)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • ICON San Antonio

    San Antonio, Texas

  • Local Institution - 0001

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.